
DiaMedica Therapeutics Investor Relations Material
Latest events

Status Update
DiaMedica Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from DiaMedica Therapeutics Inc
Access all reports
DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious diseases, with an emphasis on acute ischemic stroke (AIS) and cardio-renal diseases. The company is dedicated to improving patient outcomes by advancing its lead product candidate, DM199, which is a synthetic version of the human tissue kallikrein-1 (KLK1) protein. The company is headquartered in Minneapolis, Minnesota, and its shares are listed on the Nasdaq.
Key slides for DiaMedica Therapeutics Inc


Status Update
DiaMedica Therapeutics Inc


Status Update
DiaMedica Therapeutics Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
DMAC
Country
🇺🇸 United States